Key facts
- The Trump administration is restricting synthetic kratom versions.
- This policy shift is seen as a win for makers of rival botanical supplements.
- Industry lobbying influenced the Trump administration's kratom policy.
- Figures with financial ties to kratom companies influenced the policy.
- The policy could boost sales for certain supplement producers.
- A U.S. District Judge granted Anthropic a preliminary injunction.
- The injunction blocks the Pentagon from designating Anthropic a "supply chain risk."
- Anthropic can continue competing for defense contracts.
- Anthropic has filed a lawsuit against the Pentagon's designation.
The Trump administration's policy regarding synthetic kratom versions is perceived as a significant advantage for manufacturers of competing botanical supplements. This policy adjustment is reportedly influenced by lobbying efforts from the industry and by individuals who possess financial connections to kratom companies. The potential outcome of this shift could lead to increased sales for specific supplement producers.
In a separate development, the AI company Anthropic has received a preliminary injunction from a U.S. District Judge. This injunction halts the Pentagon's designation of Anthropic as a "supply chain risk." The ruling permits Anthropic to continue its participation in bidding for defense contracts while its ongoing lawsuit challenging this designation proceeds. However, the legal status for Anthropic remains subject to uncertainty as the litigation unfolds.